Abstract: Precocious pubarche (PP) is defined as the onset of pubic hair at 8 years of age in girls and at 9 years of age in boys. PP is idiopathic (IPP) in most children, but it is the earliest manifestation of non-classical congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency (NC21OHD) in 5 % -20 % of cases. 17-Hydroxyprogesterone (17OHP) levels after ACTH stimulation test are used to distinguish the two forms. We studied clinical indicators of NC21OHD in 289 PP children: 14 (4.8 % ) showed post-ACTH 17OHP levels > 30 nmol/L and NC21OHD due to CYP21A2 gene mutations was confirmed. NC21OHD children were younger (p: 0.006) and thinner (p: 0.003) than IPP children. Height standard deviation score (SDS) was not different (p: 0.97). NC21OHD girls showed more advanced bone age than IPP girls (p < 0.001). Earlier PP onset and bone age advance suggest NC21OHD, which requires confirmation by an ACTH stimulation test. Later, PP appearance in overweight children suggests IPP and could merit only clinical monitoring.
Introduction
The development of pubic hair (pubarche), usually associated with axillary hair and adult apocrine body odor, is the consequence of adrenarche. Adrenarche is the normal maturation of the adrenal zona reticularis in both boys and girls, beginning physiologically at 5 -6 years of age, with increased production of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). The physical changes are related to the conversion of weak androgens, such as DHEA, to more active and potent androgens (1) . Precocious pubarche (PP) is defined as the appearance of pubic hair before the ages of 8 years in girls and 9 years in boys, without other signs of puberty or virilization. PP occurs more frequently in girls than in boys by a ratio of approxi mately 9:1 (2) . The majority of children with PP have idiopathic precocious pubarche (IPP) due to a premature but normal adrenal androgen secretion. An increased sensitivity of the hair follicle to normal androgen levels has also been proposed in children with PP and normal hormonal levels (3) . In 5 % -20 % of cases, however, PP is the earliest manifestation of non-classical 21-hydroxylase deficiency (NC21OHD) due to mild mutations of the CYP21A2 gene encoding the 21-hydroxylase enzyme (4) . The reduction of 21-hydroxylase enzymatic activity causes excessive adrenal androgen secretion (4) . NC21OHD prevalence has been estimated to be between 0.1 % and 3 % , depending on ethnicity. The highest frequency occurs at 1:27 in Ashkenazi Jews, whereas disease prevalence has been reported as 1:300 in the American population of Italian ancestry (4) . If not promptly diagnosed, NC21OHD can lead to accelerated bone maturation and short final height in children (5) and severe acne, hirsutism and polycystic ovary syndrome in adults (6) . NC21OHD is currently diagnosed by elevated 17-hydroxyprogesterone (17-OHP) and delta-4-androstenedione levels after an adrenal stimulation test with synthetic ACTH (7, 8) . To date, no clinical feature has been considered sufficiently effective at predicting NC21OHD. Molecular analysis is expensive and not always routinely available; considering the low prevalence of CYP21A2 gene mutations in children presenting with PP, it cannot be proposed as a first screening test in all children. Thus, many authors believe that an ACTH stimulation test should be performed in all children presenting with PP to verify the absence of NC21OHD (9 -12) , even if the test is relatively stressing and the results are normal in more than 80 % of cases.
The aim of the present study was to identify predictive factors of NC21OHD, by analysis of the clinical, anthropometric and hormonal features of a large group of children presenting with PP.
Methods

Patients
An observational prospective study was performed, including consecutive children referred to the Outpatient Endocrine Clinic of Bambino Ges ù Children ' s Hospital-Rome for PP onset. The study began on 1 st January 2009 and concluded on 31 st December 2011. Patients with concurrent clinical signs of central precocious puberty (breast development before age 8 in girls or testicular development before age 9 in boys) were excluded. Children presenting with clinical signs suggestive of adrenal tumors (rapidly progressive systemic virilization) or Cushing syndrome (both endogenous abnormal cortisol secretion and chronic steroid therapy) were also excluded.
All subjects underwent a fi rst evaluation, including a detailed medical history, physical examination and bone age. The patient ' s age at PP onset was recorded. For all patients, weight was assessed using a digital scale and height using a Harpenden stadiometer. Body mass index (BMI) was calculated from the ratio of weight/ height 2 (kg/m 2 ). BMI and height were expressed as standard deviation score (SDS) using the Italian reference data (13) . Pubertal stage was assessed by physical examination according to the criteria of Tanner for breast development in females (14) and according to a modifi ed genital staging method based on the average volume of both testes in males (15) . A single observer (CB) performed a boneage assessment using the Greulich and Pyle method (16) . Bone age advance was defi ned as the diff erence between bone age and chronological age expressed in years. According to the specifi c clinical protocol routinely used in our unit, all PP children underwent early morning (between 0700 and 0800 am) evaluation of basal androgen and precursor levels (delta-4-androstenedione, DHEAS, testosterone and 17OHP) and ACTH stimulation test (Synachten-Defi ante Farmaceutica, Madeira, Portugal, 250 μg intravenously). Children with post-ACTH 17-OHP levels > 30 nmol/L, which is considered suggestive of NC21OHD (7, 8) , underwent confi rming mutational analysis of the CYP21A2 gene.
The Institutional Review Board of Bambino Gesù Children's Hospital in Rome (Italy) approved the research protocol. Informed consent of the patients and/or their parents was not judged necessary for this type of observational study, but written informed consent for molecular analyses was obtained.
Hormone assay
Commercial kits were used for the estimation of 17-OHP [radioimmunoassay (RIA), ICN-Pharmaceutical Inc., Costa Mesa, CA, USA]. Mean intra-and inter-assay coeffi cients of variation were 8.8 % and 12 % , respectively. Testosterone levels were measured by chemiluminescence immunoassay (Centaur-Bayer provided by Siemens Medical Solutions Diagnostics, Dublin, Ireland), intra-and inter-assay coeffi cients of variation were 3.8 % and 5 % , respectively. Delta-4-androstenedione and DHEAS levels were measured by chemiluminescence using Siemens IMMULITE-2000 XP analyzer (Siemens Healthcare Diagnostic Products, Milan, Italy). Delta-4-androstenedione inter-and intra-assay variability coeffi cients were 10 % and 6 % , respectively. DHEAS interand intra-assay variability coeffi cients were 9 % and 5 % , respectively.
Statistical analysis
Statistical analyses were conducted using STATA Statistical Soft ware Package, Release 8.0 (STATA, College Station, TX, USA). Due to the small number of patients with NC21OHD, the Mann-Whitney test was used to analyze the diff erences between medians of clinical and hormonal parameters in the two groups (NC21OHD vs. IPP children). Diff erences were considered statistically signifi cant at p < 0.05.
Results
A total of 415 children referred for PP were initially evaluated. One-hundred and fourteen children (100 females and 14 males) were excluded due to concurrent signs of precocious puberty. One female patient was excluded due to signs of severe virilization, and she was later found to be affected by adrenal carcinoma. One patient was excluded due to iatrogenic Cushing syndrome. Ten patients were excluded because they were lost at followup before undergoing the ACTH stimulation test. A total of 289 consecutive children completed all the investigations and were included in the analysis; 283 children were white Caucasians of Italian ancestry, two girls were black Africans, two girls were Indians, one girl was Chinese and one boy was Hispanic. They represented 4.5 % of the total number of children referred to our Endocrine Out patient Clinic for suspicion of an endocrine disorder during the study period (289/6480 evaluations). PP appearance was reported within 2 months prior to the evaluation in all cases. Gender distribution showed an unusually high proportion of males (53 children, 18.3 % ). Fourteen patients (4.8 % ) showed post-ACTH 17OHP levels > 30 nmol/L (10 ng/mL); all of these children were white Caucasians of Italian ancestry. Molecular analysis confirmed NC21OHD, due to mutations of the CYP21A2 gene encoding 21-hydroxylase enzyme in all of them. Clinical characteristics of NC21OHD children are shown in Table 1 . Basal levels of 17OHP were > 6 nmol/L (2 ng/mL) in 12/14 (85.7 % ) children with confirmed congenital adrenal hyperplasia (CAH) and in 20/275 (7.2 % ) children with IPP. Differential clinical, anthropometric and hormonal features of children affected by IPP and NC21OHD are given in Table 2 . NC21OHD patients were significantly younger at PP onset, whereas the BMI SDSs of NC21OHD children were significantly lower than those of IPP children. Bone age advance was > 1 year in 115/275 IPP children (41.8 % ), 51 IPP children (18.5 % ) were obese (BMI SDS > 2), 25 children (9.1 % ) showed both obesity and bone age advance > 1 year. No obese children were observed in the NC21OHD group, whereas 11/14 (78.5 % ) NC21OHD children showed bone age advance > 1 year. All NC21OHD females were younger than 6.5 years at PP onset, and all males were younger than 8 years. Height SDS was not significantly different in the two groups. Twelve children (4.1 % ) were younger than 2 years at PP onset, one of them showed a stimulated 17OHP suggestive of NC21OHD. Median levels of testosterone and delta-4 androstenedione were significantly higher in patients with NC21OHD, but two NC21OHD children (one male and one female) showed undetectable levels of testosterone ( < 0.3 nmol/L). No differences in median DHEAS levels were evident between the two groups. Considering males and females separately (Tables 3 and 4 ) , bone age advance was found to be significantly higher in NC21OHD female patients in comparison to IPP females, while the difference did not reach statistical significance in the group of males. The difference in age at PP onset was not significant in males, whereas the difference in BMI SDS was confirmed in both sexes. Table 4 Clinical and hormonal characteristics of males with IPP and NC21OHD. Data are shown as median (range). PP, precocious pubarche; IPP, idiopathic precocious pubarche; BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate.
Discussion
PP is a relatively common reason for children (particularly girls) to present either to a general pediatrician or to an endocrine clinic. To date, no clinical feature has been defined as a specific predictor of NC21OHD in children with PP, even if previous studies reported that patients with NC21OHD, in comparison with those with IPP, are taller and show accelerated bone maturation (5, 8, 16) . In a recent retrospective study, Armengaud at al. (17) did not identify any clinical predictor of NC21OHD in a large group of children presenting with PP, even if NC21OHD children were slightly heavier, with a median BMI SDS of 1.03, vs. 0.8 in IPP children (p: 0.09). In contrast with that study, we observed statistically significant differences in median age at PP onset and BMI SDS between patients with NC21OHD and IPP. Median BMI SDS was significantly higher in the IPP group than in the NC21OHD group, and a relatively high proportion of obese children were observed in the IPP group. Bone age advance was slightly more evident in the NC21OHD group than in the IPP group, even if the difference was statistically significant only in females, probably in relation to the small number of NC21OHD males. In our study, height SDS was not significantly different in the two groups. The relatively low adrenal androgen levels and the early referral of children, just a few weeks after PP appearance, probably contributed to the lack of any evident height growth acceleration in the NC21OHD children. At PP onset, all NC21OHD females were younger than 6.5 years, and all NC21OHD males were younger than 8 years. The relatively high number of very young children ( < 2 years) presenting with IPP is surprising and could suggest the impact of environmental factors. Early dietary changes (especially high animal protein intake) and several endocrine disruptors (18, 19) have been reported as associated with the appearance of PP in infants and toddlers. Previous studies and guidelines present widely varying indications for ACTH stimulation tests in patients with PP. Many authors assert that all children presenting with PP should undergo ACTH stimulation test to verify the absence of NC21OHD (9 -11, 20 -22) . Basal and post-ACTH 17OHP values may be plotted in a nomogram, which reflects the different degrees of hormonal defect in patients with classical and non-classical congenital adrenal hyperplasia, and heterozygous carriers of a CYP21A2 mutation (7) . Patients with NC21OHD typically aggregate midway down the regression line with post-ACTH 17OHP levels between 30 and 300 nmol/L (10 -100 ng/mL). The application of this systematic strategy assures 100 % sensitivity for NC21OHD diagnosis but produces normal ACTH stimulation tests in more than 80 % of patients.
Other authors suggest a selective approach toward ACTH stimulation tests for patients with " high " basal 17-OHP or delta-4-androstenedione plasma levels (12, 23 (24) . In the study by Armengaud et al. (17) , three different plasma predictors of NC21OHD in children with PP were proposed: basal 17-OHP plasma levels > 2-ng/mL (6 nmol/L) offered 100 % sensitivity and 99 % specificity for the diagnosis of NC21OHD, whereas basal levels of delta-4-andro stenedione > 0.95 ng/mL (0.03 nmol/L) or basal levels of testosterone > 0.15 ng/mL (0.5 nmol/L) were strongly and significantly associated with a NC21OHD diagnosis, even if sensitivity and specificity were lower. The results of our study are clearly in contrast with the findings of Armengaud et al. (17) , but support previous data from our group (9, 25) , which indicates that basal 17OHP levels are not useful to rule out NC21OHD. We found, indeed, that 20 IPP children had basal levels of 17OHP > 6 nmol/L (2 ng/mL), whereas basal 17OHP was < 6 nmol/L in two NC21OHD children (calculated sensitivity, 85.7 % ; specificity, 93.2 % ). Furthermore, even though the median levels of testosterone and delta-4-androstenedione were significantly higher in the NC21OHD group, two NC21OHD children showed undetectable levels of testosterone. It has been reported that commercial RIA kits are prone to overestimate adrenal hormone and precursor levels. Current standards now call for the more accurate mass spectrometry (26) . The use of a RIA method for the estimation of 17-OHP levels might explain the relatively high proportion of IPP children showing high basal levels of this precursor.
In conclusion, our study seems to confirm that high basal levels of adrenal androgens may support the clinical suspicion of NC21OHD, but normal levels of these hormones do not rule out it. An earlier onset of PP and a significant bone age advance may represent good clinical indicators of NC21OHD, requiring confirmation by an ACTH stimulation test and eventually mutational analysis. The age limits to define PP maintain a clinical usefulness. Nevertheless, considering the " epidemic " of childhood overweight and obesity, they probably do not represent a strict and absolute criterion to prescribe an ACTH stimulation test. A relatively older age at PP appearance in overweight or obese children should probably be considered strongly suggestive of IPP and may require only a careful clinical follow-up to verify that central puberty proceeds normally.
